The direct-to-consumer (DTC) telemedicine industry, including teledermatology, has seen rapid expansion in recent years, partly because of the COVID-19 pandemic. The shortage of dermatologists and the visual nature of dermatologic conditions attracted DTC companies to dermatology. As more patients continue to seek medical consultations and prescription medications from these for-profit companies, we must approach their growth with healthy skepticism. Shortcomings of DTC teledermatology include concerns about conflicts of interest (COIs), overdiagnosis, and overprescribing. Although DTC teledermatology is certainly here to stay, an appropriate understanding of this industry will allow dermatologists to advise patients and advocate for best practices.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.12788/cutis.0503 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Patient-reported treatment outcomes and safety of direct-to-consumer teledermatology for finasteride treatment in male androgenetic alopecia: A cross-sectional study.
Digit Health
October 2023
Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Objective: The use of direct-to-consumer (DTC) teledermatology platforms has increased, particularly for androgenetic alopecia (AGA). However, little is known about the efficacy and safety of these platforms. This study aimed to investigate the patient-reported treatment outcomes and safety of DTC teledermatology for the finasteride treatment of male AGA.
View Article and Find Full Text PDFDirect-to-Consumer Teledermatology Growth: A Review and Outlook for the Future.
Cutis
April 2022
Mr. Ranpariya and Dr. Kats are from Rutgers Robert Wood Johnson Medical School, Piscataway, New Jersey. Dr. Lipoff is from the Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
The direct-to-consumer (DTC) telemedicine industry, including teledermatology, has seen rapid expansion in recent years, partly because of the COVID-19 pandemic. The shortage of dermatologists and the visual nature of dermatologic conditions attracted DTC companies to dermatology. As more patients continue to seek medical consultations and prescription medications from these for-profit companies, we must approach their growth with healthy skepticism.
View Article and Find Full Text PDFResponse to Ranpariya et al's "Direct-to-consumer teledermatology platforms may have inherent conflicts of interest".
J Am Acad Dermatol
May 2022
The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, New York. Electronic address:
Accessibility of direct-to-consumer teledermatology to underserved populations.
J Am Acad Dermatol
March 2022
Department of Dermatology, New York Medical College, Valhalla, New York; Department of Dermatology, Coney Island Hospital, Brooklyn, New York; Department of Dermatology, Cumberland Diagnostic and Treatment Center, Brooklyn, New York. Electronic address:
The policy dimensions, regulatory landscape, and market characteristics of teledermatology in the United States.
JAAD Int
December 2020
Department of Dermatology, Mayo Clinic, Scottsdale, Arizona.
The COVID-19 pandemic has spurred healthcare systems across the world to rapidly redesign their models of care delivery. As such, this pandemic has accelerated the adoption of teledermatology in the United States. However, it remains unknown whether this momentum will be maintained after the pandemic.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!